January 1, 2002Seminars in Thrombosis and Hemostasis

Anticoagulants in Thrombosis and Cancer: The Missing Link

View Full Paper

Ask AI

Bookmark

Population

Cancer patients with thrombosis or hypercoagulable state

Design

Review

Authors

SMShaker A. MousaUniversity of North Carolina at Chapel Hill

Discussion

Member takes

Implication

Should not yet change UFH-to-LMWH practice in cancer DVT; hypothesis-generating for antitumor effects beyond anticoagulation.

Structured PICO

Population

Cancer patients with thrombosis or hypercoagulable state

Intervention

Anticoagulants including unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), warfarin, anti-factor VIIa, and recombinant tissue factor pathway inhibitor

Outcome

Survival, tumor growth, metastasis, and angiogenesis

Anticoagulants such as LMWH and warfarin may offer survival benefits in cancer patients with thrombosis by interfering with processes involved in tumor growth and metastasis.

Cite This Study

Shaker A. Mousa (2002) studied this question.

synapsesocial.com/papers/6a702bf66c240de38cdbb3d8 https://doi.org/10.1055/s-2002-20559

Topics

Anticoagulation in AF

View Full Paper

Ask AI

Bookmark

Anticoagulants in Thrombosis and Cancer: The Missing Link

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Topics

Anticoagulants in Thrombosis and Cancer: The Missing Link

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider